September 2020



Boston, US

We are exhibiting and presenting at TIDES US.

Come and meet the teams:

LGC Biosearch on booth #307

LGC Axolabs on booth #207


Breakfast Spotlight Presentation- Day 2 - Wednesday, May 13

Juergen Mueller, Commercial Director Nucleic Acid Therapeutics and Catherine McKeen, Site Operational Director / Head of Chemistry, will be presenting on the following:

"LGC’s Development of a Novel, Modular, GalNAc Cluster Access, and Conjugation Strategies for Nucleic Acid Medicines".


TIDES offers separate tracks covering the latest oligonucleotide and peptide development strategies from discovery, nonclinical, clinical and CMC to late-stage development and commercialization.

Oligonucleotide Tracks:

  • Chemistry, Manufacturing & Controls: Comprehensive CMC, analytical, manufacturing and regulatory strategies for both drug substance and drug product to accelerate oligonucleotide product development.
  • Discovery, Preclinical and Clinical: Design oligonucleotides with better drug-like properties to accelerate your products to the clinic and to market. The latest preclinical and clinical updates to benchmark your research and improve your clinical efforts.

Peptide Tracks:

  • Chemistry, Manufacturing & Controls: Improve process efficiencies and overcome challenges in process development, CMC and manufacturing. Understand regulatory expectations, new technologies and alternative approaches for emerging complex molecules.
  • Discovery, Preclinical and Clinical: Explore new frontiers in peptide synthesis, discovery, design and engineering to improve targeting, delivery and drug-like properties. Case studies on the latest preclinical and clinical successes of peptides and peptide-like scaffolds and structures.


For more information, or to register please visit: TIDES US